Kopra Bio
Kopra Bio engineers tumor cells to become in‑situ factories of immunotherapy, delivering localized, self‑amplifying cancer treatment.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $150M
AI Company Overview
Kopra Bio engineers tumor cells to become in‑situ factories of immunotherapy, delivering localized, self‑amplifying cancer treatment.
OncologyImmunology
Technology Platform
A proprietary gene‑therapy platform that uses tumor‑selective viral vectors to program cancer cells to produce immunomodulatory proteins locally.
Opportunities
Successful IND filing and early‑phase trials could unlock partnerships with major pharma seeking in‑situ immunotherapy solutions.
Risk Factors
Delivery efficiency of viral vectors and regulatory pathways for novel gene‑therapy immunotherapies remain uncertain.
Competitive Landscape
Differentiates from CAR‑T and systemic cytokine therapies by delivering localized, self‑amplifying immunomodulation, though faces competition from other in‑situ gene‑therapy platforms.